GlassScriptPhysician profile
Elina Zakin
NPI 1811230543
$2,235.22
in general payments reported to CMS, 2019-2025
10 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $11.45 · 2021: $53.70 · 2022: $289 · 2023: $361 · 2024: $654 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $902.79 | 2022-2025 | Botox |
| Alexion Pharmaceuticals, INC. | $368.08 | 2019-2024 | Ultomiris |
| Argenx US, INC. | $270.36 | 2023-2025 | Vyvgart Hytrulo |
| Allergan, INC. | $235.08 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $158.30 | 2022 | |
| Alnylam Pharmaceuticals INC. | $145.20 | 2019-2023 | Amvuttra |
| Ucb, INC. | $64.10 | 2025 | |
| Grifols USA, LLC | $53.61 | 2024-2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $19.52 | 2025 | Radicava |
| Astrazeneca Pharmaceuticals LP | $18.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elina Zakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.